lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
{\displaystyle Q={\begin{pmatrix}{-(x_{1}+x_{2}+x_{3})}&x_{1}&x_{2}&x_{3}\\{\pi _{1}x_{1} \over \pi _{2}}&{-({\pi _{1}x_{1} \over \pi _{2}}+x_{4}+x_{5})}&x_{4}&x_{5}\\{\pi _{1}x_{2} \over \pi _{3}}&{\pi _{2}x_{4} \over \pi _{3}}&{-({\pi _{1}x_{2} \over \pi _{3}}+{\pi _{2}x_{4} \over \pi _{3}}+x_{6})}&x_{6}\\{\pi _{1}x_{3} \over \pi _{4}}&{\pi _{2}x_{5} \over \pi _{4}}&{\pi _{3}x_{6} \over \pi _{4}}&{-({\pi _{1}x_{3} \over \pi _{4}}+{\pi _{2}x_{5} \over \pi _{4}}+{\pi _{3}x_{6} \over \pi _{4}})}\end{pmatrix}}}
In 1983 debts to the bank had reached about £1.4 million, but were reduced when Optim bought Digico's maintenance contracts with about 1,500 customers for £750,000 in autumn 1983. The company had lost £2.5 million over the previous two years on an annual turnover of about £4 million (equivalent to £13,600,000 in 2025), and had closed its Letchworth factory retaining about 50 employees. Digico was acquired from the receiver by Centreway Industries plc for £265,000 in March 1984 and merged into its computer group.
== Limitations == With radioligand therapy, there is always the risk of damage to non-cancerous surrounding tissues along with radioisotope toxicity which is always a challenge in determining how to administer and create the radioligand. Furthermore, the radioligand vial is only viable for a limited time and under specific conditions which challenges transport and storage along with feasible application to the patient. Another limitation is the lack of centers that have trained personnel and equipment for radioligand therapy. Furthermore, individual characteristics affect the exact radiosensitivity to the therapy (thus affecting dosimetry) and are hard to predict without radiobiological models.
A study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after a treatment seems to work in phases I and II. Phase III trials may include hundreds of people. (NCI) Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. (NLM) Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 studies usually include from several hundred to several thousand subjects. (21CFR312) Phase IV clinical trial
The season premiered on the streaming service Amazon Prime Video on June 3, 2022, with its first three episodes. The remaining five episodes were released weekly until July 8, 2022. The season received critical acclaim with praise towards its action sequences, social commentary, visual effects, character development, story, and performances (particularly Urban, Quaid, Starr, McElligott, Alonso, and Ackles). This season is widely regarded as the best season of the show. It received multiple nominations including two Primetime Creative Arts Emmy Awards, earning one for stunt coordination. On June 10, 2022, the series was renewed for a fourth season.
Sources: en.wikipedia.org
== Management == BACM may be alarming to parents and lead to unnecessary extensive tests. Treatment consists of oral analgesics, rest, and adequate hydration. Hospitalization is usually not necessary. Full recovery can be expected within a week, however, recurrences can occur.
The Prachachat Party issued a statement asking the Election Commission to investigate irregularities in Pattani and Narathiwat Constituency 4, and the Bhumjaithai candidate in Narathiwat Constituency 3 asked for a recount in that constituency. Former Election Commission member Somchai Srisutthiyakorn criticized the commission's failure to comply with regulations in Chonburi Constituency 1, stating that election showed serious signs of fraud. He further stated that even a recount might not be enough due to the possibility of tampering with improperly sealed boxes and suggested that a repeat election might have to be held in the constituency. On 12 February, the Election Commission rejected the requests for recounts in Chonburi and Maha Sarakham, stating that its investigation did not find credible evidence. In the same press briefing, it ordered new elections for three polling stations: one in Bangkok where ballots were damaged by rain, and two in Nan and Udon Thani, where polling station officials incorrectly tore ballots. It also ordered a recount of the votes in Pathum Thani Constituency 7, which had been subject to complaints that officials failed to properly count votes in view of the public. Further recounts at eight stations and a fresh election at one station were announced on 17 February, and nine more on 24 February.
The use of different fuels in nuclear reactors results in different spent nuclear fuel (SNF) composition, with varying activity curves. The most abundant material being U-238 with other uranium isotopes, other actinides, fission products and activation products. Long-lived radioactive waste from the back end of the fuel cycle is especially relevant when designing a complete waste management plan for SNF. When looking at long-term radioactive decay, the actinides in the SNF have a significant influence due to their characteristically long half-lives. Depending on what a nuclear reactor is fueled with, the actinide composition in the SNF will be different. An example of this effect is the use of nuclear fuels with thorium. Th-232 is a fertile material that can undergo a neutron capture reaction and two beta minus decays, resulting in the production of fissile U-233. The SNF of a cycle with thorium will contain U-233. Its radioactive decay will strongly influence the long-term activity curve of the SNF for around a million years. A comparison of the activity associated to U-233 for three different SNF types can be seen in the figure on the top right. The burnt fuels are thorium with reactor-grade plutonium (RGPu), thorium with weapons-grade plutonium (WGPu), and Mixed oxide fuel (MOX, no thorium). For RGPu and WGPu, the initial amount of U-233 and its decay for around a million years can be seen. This has an effect on the total activity curve of the three fuel types.
== Transportation == Retford railway station, Nottinghamshire, England (station code: RET) Rotterdamse Elektrische Tram, the main public transport operator of Rotterdam, the Netherlands Røst Airport, Norway (IATA code) Rapid-exit taxiway allowing an aircraft to leave a runway quickly
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.